Ultragenyx Pharmaceutical Inc. (RARE) intrinsic value & 10-year financials
Ultragenyx Pharmaceutical Inc. (RARE) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 158.0% a year to $673.0M, with an average return on invested capital of -149.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $14.54
- Market cap
- $1.4B
- Revenue (FY2025)
- $673.0M
- Revenue growth (10-yr CAGR)
- 158.0%
- ROIC (10-yr avg)
- -149.9%
- Free cash flow (FY2025)
- -$472.0M
RARE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $673.0M | -$575.0M | -$5.83 | -$472.0M | -79.5% | 292.8% |
| FY2024 | $560.2M | -$569.2M | -$6.29 | -$421.7M | -95.7% | -525.5% |
| FY2023 | $434.2M | -$606.6M | -$8.25 | -$519.1M | -131.1% | -342.1% |
| FY2022 | $363.3M | -$707.4M | -$10.12 | -$496.6M | -178.6% | -146.6% |
| FY2021 | $351.4M | -$454.0M | -$6.70 | -$411.8M | -108.6% | -67.8% |
| FY2020 | $271.0M | -$186.6M | -$3.07 | -$176.1M | -121.8% | -90.4% |
| FY2019 | $103.7M | -$402.7M | — | -$370.2M | -409.0% | -169.7% |
| FY2018 | $51.5M | -$197.6M | — | -$294.6M | -721.2% | — |
| FY2017 | $2.6M | -$302.1M | — | -$256.6M | -12593.5% | — |
| FY2016 | $133.0K | -$245.9M | — | -$171.2M | -186471.4% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ultragenyx Pharmaceutical Inc. is a consistent compounder, expanding top-line revenue at 158.0% annually over the past decade.
Ultragenyx Pharmaceutical Inc. has historically struggled to out-earn its cost of capital, averaging just -44.6% ROIC.
Ultragenyx Pharmaceutical Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Ultragenyx Pharmaceutical Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-193.65 per share.